Top Venture Capital Firms in San Diego
San Diego has quietly built one of the more structurally diverse venture ecosystems in the United States, running parallel to but distinct from the Bay Area's gravitational pull. Its strengths are well-documented in the numbers: the region pulled in $1 billion in VC funding in Q1 2025 alone, driven by a concentration of biotech, life sciences, defense technology, and a growing enterprise software base anchored around the UC San Diego research corridor.
The firms operating here range from multi-hundred-million-dollar funds with national footprints to sub-$10M micro-funds targeting the earliest pre-seed checks, which means the right fit for any given founder depends heavily on stage and sector.
The directory tool above lists every venture capital firm PEL currently tracks in San Diego, filterable by industry focus, investment stage, geography, and check size. What follows below is the context that the table cannot provide: what actually distinguishes each firm, who each one suits, and where the meaningful differences lie across this particular cohort.
1. Section 32
Bill Maris built Google Ventures into one of the most active corporate venture platforms in the world before leaving in 2016 to found Section 32 on his own terms. The firm closed its most recent fund at $740 million and now manages over $1 billion in total assets, making it by total capital the largest pure-play VC firm in this cohort. With 128 investments on record and over 150 exits, Section 32 has one of the most active deployment histories of any San Diego-headquartered fund.
The firm targets technology and healthcare companies, which in practice means the intersection of the two: digital health, medical devices, life sciences software, and adjacent computational fields. Typical check sizes run from $5 million to $20 million, so this is not a firm founders should approach at idea stage.
The backing of Maris's prior track record and the fund's scale means Section 32 can credibly lead rounds and carry portfolio companies through multiple stages.
2. Harpoon Ventures
Harpoon's trajectory across four funds illustrates how quickly a thesis can scale when it's differentiated from the start. Fund I was approximately $3 million. Fund IV closed at $155 million, bringing total AUM past $450 million. The firm was founded by Larsen Jensen, a two-time Olympic medalist and former Navy SEAL, and that background is not incidental to the strategy: Harpoon focuses on critical and defense-adjacent technologies, national security applications, and the deep tech sectors that typically require founders who understand how government and military procurement actually works.
Check sizes average $100,000 to $5 million, which gives the firm flexibility across early seed to Series A. Founders in defense tech, aerospace, cybersecurity, or dual-use hardware who want a lead investor with operational credibility in those specific verticals will find few better-positioned funds in the region.
3. Black Flag
Founded in 2025, Black Flag is the newest firm in this group and structurally the most unusual. It operates as a virtual rolling accelerator, investing $250,000 to $1 million per company in critical technologies for national security and national defense. The connection to Harpoon Ventures is direct: the firm shares founding DNA with Harpoon, including Larsen Jensen, meaning Black Flag functions in practice as an earlier-stage entry point into the same defense-tech ecosystem that Harpoon backs at larger check sizes.
For pre-seed founders in national security technology who want more than a check, specifically the network and domain fluency that comes from founders who have operated in those environments, Black Flag's rolling accelerator structure is worth understanding before approaching either firm independently.
4. Boxer Capital
Boxer Capital is the venture arm of Tavistock Group, the private investment organization founded by billionaire Joe Lewis. That structural fact matters because it means Boxer operates with patient, proprietary capital rather than the LP-return timelines that govern most VC funds. The firm focuses on biotechnology, specialized medicine, and precision medicine, with a stated investment horizon of three to five years.
Form ADV filings show approximately $578 million in discretionary AUM. PEL's own database reflects a larger figure closer to $2.5 billion, which likely captures Tavistock's broader capital base. Founded in 2005, Boxer has over two decades of research-driven biotech investing in San Diego, giving it deep relationships across the local biotech ecosystem that a newer fund would take years to replicate.
5. Correlation Ventures
Most venture firms describe themselves as data-driven. Correlation Ventures has built its entire model around it. The San Diego firm uses quantitative analysis of historical venture outcomes to inform investment decisions, a structural distinction from the relationship-first pattern matching that dominates most early-stage VC. Fund III closed at $130 million in 2023, bringing total AUM to approximately $500 million across the firm's history since 2006.
The mechanics reflect the thesis: Correlation writes $100,000 to $4 million checks and targets more than 100 companies per fund, deliberately maintaining a high-volume, diversified portfolio. This is not a firm that takes board seats or leads rounds in the conventional sense.
Founders who want a fast, low-friction co-investor that moves on data rather than relationship cycles will find Correlation unusually efficient to work with, particularly at early stages where decision speed matters.
6. HealthpointCapital
Specialization this narrow is rare in any asset class. HealthpointCapital invests exclusively in musculoskeletal healthcare, covering orthopedics, spine, sports medicine, and related surgical and implant technologies. The firm was founded in 2002 and manages approximately $800 million in institutional capital, with Fund IV targeting $500 million and an initial closing of $100 million already secured.
Headquarters are listed in San Diego with New York operational presence, which reflects the firm's positioning as a nationally active specialist rather than a purely regional fund. For medtech founders working anywhere in the musculoskeletal space, HealthpointCapital is one of a very small number of institutional investors globally that brings both the sector depth and the capital scale to be a meaningful growth-stage partner.
7. Keshif Ventures
Taner Halicioglu founded Keshif Ventures and has backed approximately 82 companies through it, a notable deal count for a fund with $8 million in AUM. That ratio reflects a micro-fund strategy built around concentration in San Diego's data science and enterprise software ecosystem specifically, with infrastructure and B2B software as recurring themes. Exits include Abreos Biosciences, BioAtla, Portfolium, and Stemonix, which span biotech and edtech alongside the core software focus.
Founded in 2012, Keshif is one of the older locally-rooted funds in this cohort, and its exit record across sectors suggests Halicioglu has operated more as a conviction-driven angel at institutional scale than as a traditional fund manager optimizing for portfolio construction. Founders at the earliest stages in San Diego's enterprise and data infrastructure community will find Keshif one of the most accessible entry points for a local check.
8. Ganas Ventures
Ganas Ventures targets a founder population that most San Diego funds are not structured to reach. Founded in 2022 by Lolita Taub, the firm raised a $10 million Fund I and writes $100,000 checks into pre-seed and seed-stage companies building community-driven products in both Web2 and Web3. The geographic scope spans the US and Latin America, which is atypical for a firm of this size and reflects an intentional focus on community-driven startups and underrepresented founders who operate across those markets.
At $100,000 per check and $10 million in fund capital, Ganas is not in a position to lead institutional rounds. What it offers founders at the earliest stages is conviction capital from a firm with a specific thesis about who builds the next generation of community-anchored technology, plus access to a cross-border network that most San Diego-based funds do not maintain.
9. Innovative Industrial Properties
Innovative Industrial Properties does not fit the standard venture capital profile, and including it here without that caveat would be misleading. IIPR is a publicly traded REIT on the NYSE, not a fund that takes equity stakes in startups. Its $2.5 billion in invested capital is deployed as real estate, specifically industrial and greenhouse properties leased to licensed cannabis operators across 19 states, comprising 8.9 million rentable square feet as of March 2026.
Founded in 2016, IIPR was the first publicly traded company on the NYSE focused on regulated cannabis real estate. It belongs in a venture capital directory insofar as it represents an investment vehicle in a high-growth regulated sector, but founders seeking growth equity or a board-seat investor should look elsewhere in this list.
For cannabis operators specifically seeking sale-leaseback financing or real estate capital to fund facility expansion, IIPR is one of the only institutionally scaled options in the sector.
Let’s Recap
The nine firms above cover a wider spectrum than the “San Diego VC” label suggests.
At the top of the capital stack, Section 32 and Boxer Capital both manage north of $500 million, with the scale to lead and follow on across multiple rounds. Section 32 is generalist across tech and healthcare; Boxer is a biotech specialist backed by permanent proprietary capital. HealthpointCapital sits in a narrower vertical still, musculoskeletal medicine only, but with institutional scale and a two-decade track record that makes it the default choice in that subsector.
Harpoon Ventures and Black Flag occupy the same thematic territory, defense and national security technology, at different stages:
- Harpoon Ventures: $100,000–5 million, with the fund scale to grow alongside a company.
- Black Flag: $250,000–1 million via a rolling accelerator structure, built for the pre-institutional phase.
Correlation Ventures sits apart from both structurally: a high-volume quantitative co-investor writing early checks across sectors without the board-seat expectations most lead investors carry.
At the earliest end, three firms represent very different concentrations:
- Keshif: a long-running San Diego micro-fund with a real exit record in enterprise software and data science.
- Ganas: the only firm here with an explicit cross-border US–Latin America mandate, focused on community-driven and Web3 products.
- IIPR: not a startup investor at all, but a real estate financing vehicle for cannabis operators.
To use the directory tool above most effectively: filter by stage first, then sector, then check size against your current round. A founder raising $500,000 pre-seed in defense tech will see a very different set of relevant firms than one raising a $10 million Series A in precision medicine. Stage and sector together narrow the field faster than any other pair of filters.